Active, not recruitingPhase 2NCT03492177

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

Studying Drug- or toxin-induced pulmonary arterial hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Actelion
Principal Investigator
Catherine Boisson
Actelion
Intervention
selexipag (Uptravi)(drug)
Enrollment
63 enrolled
Eligibility
2-17 years · All sexes
Timeline
20182026

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03492177 on ClinicalTrials.gov

Other trials for Drug- or toxin-induced pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Drug- or toxin-induced pulmonary arterial hypertension

← Back to all trials